Recent advances in the treatment of tobacco dependence

Clinical Neuroscience Research

Volumn 5, Issue 2-4, 2005, Pages 175-183

  Anthenelli, Robert M ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Endocannabinoid system (ECS); Mesocorticolimbic dopamine pathway; Nicotine; Nicotinic acetylcholine receptors (nAChRs); Rimonabant; Selegiline; Tobacco dependence; Varenicline

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ALCOHOL; AMFEBUTAMONE; CANNABINOID 1 RECEPTOR; CARBIDOPA PLUS LEVODOPA; CLONIDINE; COCAINE; ENDOCANNABINOID; MOCLOBEMIDE; MONOAMINE OXIDASE B INHIBITOR; NICOTINE; NICOTINE GUM; NICOTINE VACCINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NORTRIPTYLINE; PHENELZINE; RECEPTOR SUBTYPE; RIMONABANT; SELEGILINE; TRANYLCYPROMINE; UNCLASSIFIED DRUG; VACCINE; VARENICLINE;

ALCOHOLISM; CIGARETTE SMOKING; CLINICAL TRIAL; COCAINE DEPENDENCE; DRUG APPROVAL; DRUG MECHANISM; DRUG TARGETING; HUMAN; HYPERTENSIVE CRISIS; MORBIDITY; MORTALITY; NAUSEA; NEUROBIOLOGY; NICOTINE REPLACEMENT THERAPY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; TACHYCARDIA; TOBACCO DEPENDENCE;

EID: 27944434860     PISSN: 15662772     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cnr.2005.08.014     Document Type: Article

References (67)

1. A.H. Mokdad J.S. Marks D.F. Stroup J.L. Gerberding Actual causes of death in the United States, 2000 J Am Med Assoc 291 10 2004 1238-1245
2. World Health Organization. The World Health Report 2002: Reducing risks, promoting healthy life. 1-94. 2002. Geneva Switzerland: World Health Organization.
3. Centers for Disease Control and Prevention. State-specific prevalence of current cigarette smoking among adultsUnited States, 2003. MMWR Morb Mortal Wkly Rep, 2004;53(44):1035-1037.
4. J. Mackay M. Eriksen The tobacco atlas 2002 Myriad Editions Limited Brighton, United Kingdom
5. M.C. Fiore W.C. Bailey S.J. Cohen et al. Clinical practice guideline Treating tobacco use and dependence 2000 US Department of Health and Human Services Rockville, MD
6. N.A. Rigotti Clinical practice. Treatment of tobacco use and dependence N Engl J Med 346 7 2002 506-512
7. T.P. George S.S. O'Malley Current pharmacological treatments for nicotine dependence Trends Pharmacol Sci 25 1 2004 42-48
8. J. Foulds M. Burke M. Steinberg J.M. Williams D.M. Ziedonis Advances in pharmacotherapy for tobacco dependence Expert Opin Emerg Drugs 9 1 2004 39-53
9. D. Kandel K. Chen L.A. Warner R.C. Kessler B. Grant Prevalence and demographic correlates of symptoms of last year dependence on alcohol, nicotine, marijuana and cocaine in the US population Drug Alcohol Depend 44 1 1997 11-29
10. D. Kalman K. Hayes S.M. Colby C.A. Eaton D.J. Rohsenow P.M. Monti Concurrent versus delayed smoking cessation treatment for persons in early alcohol recovery. A pilot study J Subst Abuse Treat 20 3 2001 233-238
11. T.A. Burling M.A. Salvio A.L. Seidner T.G. Ramsey Cigarette smoking in alcohol and cocaine abusers J Subst Abuse 8 4 1996 445-452
12. S. Zevin S.G. Gourlay N.L. Benowitz Clinical pharmacology of nicotine Clin Dermatol 16 5 1998 557-564
13. J.A. Dani Overview of nicotinic receptors and their roles in the central nervous system Biol Psychiatry 49 3 2001 166-174
14. J.A. Dani M. De Biasi Cellular mechanisms of nicotine addiction Pharmacol Biochem Behav 70 4 2001 439-446
15. Z.M. Fagen H.D. Mansvelder J.R. Keath D.S. McGehee Short- and long-term modulation of synaptic inputs to brain reward areas by nicotine Ann NY Acad Sci 1003 2003 185-195
16. J.A. Dani Roles of dopamine signaling in nicotine addiction Mol Psychiatry 8 3 2003 255-256
17. M.R. Picciotto W.A. Corrigall Neuronal systems underlying behaviors related to nicotine addiction: Neural circuits and molecular genetics J Neurosci 22 9 2002 3338-3341
18. F.E. Pontieri G. Tanda F. Orzi G. Di Chiara Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs Nature 382 6588 1996 255-257
19. A.E. Kelley Memory and addiction: Shared neural circuitry and molecular mechanisms Neuron 44 1 2004 161-179
20. H.D. Mansvelder J.R. Keath D.S. McGehee Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas Neuron 33 6 2002 905-919
21. H.D. Mansvelder M. De Rover D.S. McGehee A.B. Brussaard Cholinergic modulation of dopaminergic reward areas: Upstream and downstream targets of nicotine addiction Eur J Pharmacol 480 1-3 2003 117-123
22. A.C. Howlett F. Barth T.I. Bonner et al. International Union of Pharmacology, XXVII. Classification of cannabinoid receptors Pharmacol Rev 54 2 2002 161-202
23. T.M. Westlake A.C. Howlett T.I. Bonner L.A. Matsuda M. Herkenham Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains Neuroscience 63 3 1994 637-652
24. M.A. Carai G. Colombo G.L. Gessa Rapid tolerance to the intestinal prokinetic effect of cannabinoid CB1 receptor antagonist, SR 141716 (Rimonabant) Eur J Pharmacol 494 2-3 2004 221-224
25. M. Bensaid M. Gary-Bobo A. Esclangon et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells Mol Pharmacol 63 4 2003 908-914
26. L. De Petrocellis M.G. Cascio V. DiMarzo The endocannabinoid system: A general view and latest additions Br J Pharmacol 141 5 2004 765-774
27. M.A. Diana A. Marty Endocannabinoid-mediated short-term synaptic plasticity: Depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE) Br J Pharmacol 142 1 2004 9-19
28. S. Gonzalez M.G. Cascio J. Fernandez-Ruiz F. Fezza V. Di Marzo J.A. Ramos Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine Brain Res 954 1 2002 73-81
29. C. Cohen G. Perrault C. Voltz R. Steinberg P. Soubrie SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats Behav Pharmacol 13 5-6 2002 451-463
30. Cohen C, Perrault G, Griebel G, Soubrie P. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: Reversal by the cannabinoid (CB(1)) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 2004.
31. D. Cota G. Marsicano M. Tschop et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis J Clin Invest 112 3 2003 423-431
32. T.L. Horvath Endocannabinoids and the regulation of body fat: The smoke is clearing J Clin Invest 112 3 2003 323-326
33. T.C. Ravinet M. Arnone C. Delgorge et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice Am J Physiol Regul Integr Comp Physiol 284 2 2003 R345-R353
34. Dale LC, Anthenelli RM. Rimonabant as an aid to smoking cessation in smokers motivated to quit: Results from a US multicenter study-STRATUS US Trial. Paper presented at the Annual Meeting of the American College of Cardiology, New Orleans, Louisiana, March 2004.
35. Despres JP. Rimonabant in obesity (RIO)-lipids trial results. Paper presented at the Annual Meeting of the American College of Cardiology, New Orleans, Louisiana, March 2004.
36. Van Gaal L. RIO-Europe: A randomized double-blind study of weight reducing effect and safety of rimonabant in obese patients who are without comorbidities. Paper presented at the European Society of Cardiology Congress, Munich, Germany, August 2004.
37. Pi-Sunyer X. Effect of rimonabant on weight reduction and weight maintenance: RIO-North America Trial. Paper presented at the Annual Meeting of the American Heart Association, New Orleans, Louisiana, November 2004.
38. M.R. Picciotto Nicotine as a modulator of behavior: Beyond the inverted U Trends Pharmacol Sci 24 9 2003 493-499
39. A.E. Kelley Nicotinic receptors: Addiction's smoking gun? Nat Med 8 5 2002 447-449
40. L.E. O'Dell A.W. Bruijnzeel S. Ghozland A. Markou G.F. Koob Nicotine withdrawal in adolescent and adult rats Ann NY Acad Sci 1021 2004 167-174
41. J.R. Hughes D. Hatsukami Signs and symptoms of tobacco withdrawal Arch Gen Psychiatry 43 1986 289-294
42. C. Silagy T. Lancaster L. Stead D. Mant G. Fowler Nicotine replacement therapy for smoking cessation Cochrane Database Syst Rev 3 2004 CD000146
43. A.R. Tapper S.L. McKinney R. Nashmi et al. Nicotine activation of alpha4* receptors: Sufficient for reward, tolerance, and sensitization Science 306 5698 2004 1029-1032
44. M.R. Picciotto M. Zoli R. Rimondini et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine Nature 391 6663 1998 173-177
45. L.M. Marubio A.M. Gardier S. Durier et al. Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors Eur J Neurosci 17 7 2003 1329-1337
46. L.E. Rueter D.J. Anderson C.A. Briggs et al. ABT-089: Pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders CNS Drug Rev 10 2 2004 167-182
47. C. Cohen O.E. Bergis F. Galli et al. SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation J Pharmacol Exp Ther 306 1 2003 407-420
48. CNNmoney. Pfizer unveils anti-smoking drug. CNNmoney 2004.
49. I. Berlin R.M. Anthenelli Monoamine oxidases and tobacco smoking Int J Neuropsychopharmacol 4 1 2001 33-42
50. I. Berlin S. Said O. Spreuz-Varoquaux R. Olivares J.M. Launay A.J. Puech Monoamine oxidase A and B activities in heavy smokers Biol Psychiatry 38 11 1995 756-761
51. J.C. Shih K. Chen M.J. Ridd Monoamine oxidase: From genes to behavior Annu Rev Neurosci 22 1999 197-217
52. J.W. Lenders G. Eisenhofer N.G. Abeling et al. Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes J Clin Invest 97 4 1996 1010-1019
53. I. Berlin S. Said O. Spreux-Varoquaux et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers Clin Pharmacol Ther 58 1995 444-452
54. J.S. Fowler J. Logan G.J. Wang et al. Low monoamine oxidase B in peripheral organs in smokers Proc Natl Acad Sci USA 100 20 2003 11600-11605
55. M.E. Bembenek C.W. Abell L.A. Chrisey M.D. Rozwadowska W. Gessner A. Brossi Inhibition of monoamine oxidases A and B by simple isoquinoline alkaloids: Racemic and optically active 1,2,3,4-tetrahydro-,e,4-dihydro-, and fully aromatic isoquinolines J Med Chem 33 1 1990 147-152
56. V. Glover J. Liebowitz I. Armando M. Sandler beta-Carbolines as selective monoamine oxidase inhibitors: In vivo implications J Neural Transm 54 3-4 1982 209-218
57. E. Mendez-Alvarez R. Soto-Otero I. Sanchez-Sellero L.M. Lopez-Rivadulla Inhibition of brain monoamine oxidase by adducts of 1,2,3,4-tetrahydroisoquinoline with components of cigarette smoke Life Sci 60 1997 1719-1727
58. J.E. Rose F.M. Behm C. Ramsey J.C. Ritchie Jr Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms Nicotine Tob Res 3 4 2001 383-390
59. R.M. Anthenelli J. Tipp T.K. Li et al. Platelet monoamine oxidase activity in subgroups of alcoholics and controls: Results from the Collaborative Study on the Genetics of Alcoholism Alcohol Clin Exp Res 22 1998 598-604
60. S.S. Watkins G.F. Koob A. Markou Neural mechanisms underlying nicotine addiction: Acute positive reinforcement and withdrawal Nicotine & Tobacco Research 2 2000 19-37
61. E.J. Houtsmuller J.A. Thornton M.L. Stitzer Effects of selegiline (L-deprenyl) during smoking and short-term abstinence Psychopharmacology (Berl) 163 2 2002 213-220
62. T.P. George J.C. Vessicchio A. Termine P.I. Jatlow T.R. Kosten S.S. O'Malley A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation Biol Psychiatry 53 2 2003 136-143
63. R. Biberman R. Neumann I. Katzir Y. Gerber A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation Addiction 98 10 2003 1403-1407
64. L.F. Martin W.R. Kem R. Freedman Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia Psychopharmacology (Berl) 174 1 2004 54-64
65. H. Kitagawa T. Takenouchi R. Azuma et al. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers Neuropsychopharmacology 28 3 2003 542-551
66. J.F. Cryan F. Gasparini G. van Heeke A. Markou Non-nicotinic neuropharmacological strategies for nicotine dependence: Beyond bupropion Drug Discov Today 8 22 2003 1025-1034
67. S.G. Gourlay L.F. Stead N.L. Benowitz Clonidine for smoking cessation Cochrane Database Syst Rev 3 2004 CD000058